Arrowhead Pharmaceuticals Enters Commercial Era with Landmark Drug Approval

The biotechnology firm Arrowhead Pharmaceuticals has reached a defining corporate milestone, transitioning from a research-focused entity to a commercial-stage company. This pivotal shift follows the regulatory clearance of its inaugural therapy, moving its core operations from clinical trials to sales execution—a critical juncture that will determine its long-term trajectory.

The company’s fiscal year ending September 30, 2025, underscores this transformation. Arrowhead reported total revenue of approximately $829.4 million. This substantial increase was primarily fueled by milestone and license payments from collaboration partners, most notably Sarepta Therapeutics, which contributed roughly $696.8 million. Consequently, the net loss narrowed significantly to about $1.63 million, indicating the company is operating near Read more...